Professor Michel Farnier

University of Bourgogne and in collaboration with the Department of Cardiology of Dijon Bourgogne Hospital

Biography

Michel Farnier, MD, PhD, is currently working in the research PEC2 team at the University of Bourgogne and in collaboration with the Department of Cardiology of Dijon Bourgogne Hospital . He graduated from Dijon University in 1974 with a Doctorate in Physical Chemistry and received his medical degree in 1981. He later completed a degree in human biology with specialization in clinical pharmacology, and also a specialization in endocrinology and nutritional diseases. He was previously Director of a Lipid Clinic in Dijon from 1990 to 2019.

Doctor Farnier is a long-standing lecturer in science and medicine at the University of Bourgogne in Dijon, and he has also contributed significantly to medical research in the areas of dyslipidaemia. His research interests include lipid-lowering strategies and the genetics of dyslipidaemia, and he has been involved in numerous clinical trials in the field of lipid lowering drugs.

Expert content

LBPMC Publications

Analysis of vitamin D levels in patients with and without statin-associated myalgia — A systematic review and meta-analysis of 7 studies with 2420 patients

Risk factors and prognostic value of endotoxemia in patients with acute myocardial infarction 2024-07-10
CONCLUSIONS: In patients admitted for MI, higher levels of endotoxins were related to pre-existing conditions rather than acute clinical severity. Therefore, endotoxins measured on the day of MI could reflect metabolic chronic endotoxemia rather than MI-related acute gut translocation.
Maxime Nguyen
Management of lipid variables in primary cardiovascular prevention: A position paper from the Heart, Vessels and Metabolism Group of the French Society of Cardiology 2024-05-18
Low-density lipoprotein cholesterol has been established as a powerful cardiovascular risk factor; its reduction provides a clinical benefit in primary cardiovascular prevention, irrespective of the characteristics of the patients treated. It is useful to tailor low-density lipoprotein cholesterol targets according to the magnitude of cardiovascular risk (low, high or very high) in order to reduce […]
François Diévart
Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia 2024-05-02
CONCLUSIONS: Real-life, long-term evinacumab adjunctive to lipid-lowering therapy including lipoprotein apheresis led to sustained low-density lipoprotein cholesterol lowering and improved cardiovascular event-free survival of patients with HoFH.
Sophie Béliard
Negative relationship between eicosapentaenoic acid and inflammatory biomarkers in patients with acute myocardial infarction 2024-01-09
No abstract
David Masson
Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study 2023-12-15
BACKGROUND: Approximately 450 000 children are born with familial hypercholesterolaemia worldwide every year, yet only 2·1% of adults with familial hypercholesterolaemia were diagnosed before age 18 years via current diagnostic approaches, which are derived from observations in adults. We aimed to characterise children and adolescents with heterozygous familial hypercholesterolaemia (HeFH) and understand current approaches to […]
European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration
Characteristics and prognosis of patients with elevated triglycerides in acute myocardial infarction: observational data from a large database over a 17-year period: High triglycerides in acute myocardial infarction 2023-11-20
From a large regional registry, we aimed to address the characteristics and prognosis of patients with elevated triglycerides (TG) among patients hospitalized for an acute myocardial infarction (MI). From the multicenter database of the RICO survey, all consecutive patients hospitalized for an acute MI (2001-2017) and alive at discharge were included. Among the 10,667 patients […]
Marianne Zeller
Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook 2023-10-12
Dyslipidemia refers to unhealthy changes in blood lipid composition and is a risk factor for atherosclerotic cardiovascular diseases (ASCVD). Usually, low-density lipoprotein-cholesterol (LDL-C) is the primary goal for dyslipidemia management. However, non-high-density lipoprotein cholesterol (non-HDL-C) has gained attention as an alternative, reliable goal. It encompasses all plasma lipoproteins like LDL, triglyceride-rich lipoproteins (TRL), TRL-remnants, and […]
Vikrama Raja
Effect of lipoprotein(a) levels on coronary lesion complexity in patients with acute myocardial infarction: data from the French RICO survey 2023-05-18
No abstract
Isabelle M Kouame
Evaluation of hypercholesterolemia management in at-risk patients by cardiologists in France: a case vignette-based study 2023-03-09
Aim: This online interactive survey investigated lipid-lowering approaches of French cardiologists in high- and very high-cardiovascular risk patients with hypercholesterolemia. Materials & methods: Physicians assessed three hypothetical patients at three clinic visits, and selected the patients' cardiovascular risk category, target low-density lipoprotein cholesterol (LDL-C) and treatment. Results: A total of 162 physicians completed 480 risk […]
Jean Ferrières
Evaluation of lipoprotein(a) in the prevention and management of atherosclerotic cardiovascular disease: A survey among the Lipid Clinics Network 2023-03-09
CONCLUSIONS: These results warrant for a great deal of effort from scientific societies to address the barriers that limit the routine use of the measurement of Lp(a) concentration and to recognise the importance of Lp(a) as a risk factor.
Alberico L Catapano
Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP) 2023-03-08
Cardiovascular disease (CVD) is a chronic non-communicable disease (NCD) and the predominant cause of morbidity and mortality worldwide. Substantial reductions in the CVD prevalence have been achieved in recent years by the attenuation of risk factors (particularly hypertension and dyslipidaemias) in primary and secondary prevention. Despite the remarkable success of lipid lowering treatments, and of […]
Maciej Banach
Burden of cardiovascular disease in a large contemporary cohort of patients with heterozygous familial hypercholesterolemia 2023-01-16
CONCLUSIONS: The incidence of cardiovascular events in HeFH is high and lipid-lowering treatment is far from optimal. The cardiovascular risk of HeFH is underestimated and patients are inadequately treated.
Jean Ferrières
Maternal Inheritance of Familial Hypercholesterolemia Gene Mutation Predisposes to Coronary Atherosclerosis as Assessed by Calcium Score in Adulthood 2022-12-29
CONCLUSIONS: Maternal inheritance of FH gene mutation was associated with more severe subclinical coronary atherosclerosis assessed by CAC score and may be considered as a potential cardiovascular risk factor.
Florian Mourre
Lipid-lowering efficacy and safety of alirocumab in a real-life setting in France: Insights from the ODYSSEY APPRISE study 2022-12-19
CONCLUSIONS: In the French setting, alirocumab was well tolerated, safe and highly effective at reducing LDL-C. These findings support the use of alirocumab to manage hypercholesterolaemia in patients at high cardiovascular risk.
Patrick Henry
Projected impact of treatment intensification with statin, ezetimibe, and statin plus ezetimibe fixed-dose combination on MACE across six countries 2022-09-22
CONCLUSION: The 2019 ESC/EAS guideline-based treatment intensification with strategies based on statin, ezetimibe, and statin plus ezetimibe FDC is estimated to result in a substantial population-level benefit in terms of MACE averted compared with BAU.
Michel Farnier